Literature DB >> 29204260

The evolving role of targeted biological agents in the management of indolent B-cell lymphomas.

Trent Peng Wang1, John Harwood Scott2, Stefan Klaus Barta3.   

Abstract

Improved understanding of the mechanisms of lymphomagenesis has resulted in a surge of development for new targeted agents. An impressive number of biological agents targeting different steps in the pathways of tumor proliferation, survival and apoptosis have become available. The management of patients with indolent non-Hodgkin lymphomas (iNHLs) is rapidly transforming with incorporation of those targeted biological agents into the front-line and relapsed/refractory setting. This review highlights several categories of novel biological agents and will discuss their potential role in the contemporary management of patients with iNHLs.

Entities:  

Keywords:  indolent lymphoma-targeted biologic therapy

Year:  2017        PMID： 29204260      PMCID： PMC5703116          DOI： 10.1177/2040620717738740

Source DB:  PubMed          Journal:  Ther Adv Hematol        ISSN： 2040-6207


  90 in total

1.  Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Authors:  Andre Goy; Anas Younes; Peter McLaughlin; Barbara Pro; Jorge E Romaguera; Frederick Hagemeister; Luis Fayad; Nam H Dang; Felipe Samaniego; Michael Wang; Kristine Broglio; Barry Samuels; Frederic Gilles; Andreas H Sarris; Susan Hart; Elizabeth Trehu; David Schenkein; Fernando Cabanillas; Alma M Rodriguez
Journal:  J Clin Oncol       Date:  2004-12-21       Impact factor: 44.544

2.  Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains.

Authors:  Jinjuan Wang; Michael Jensen; Yukang Lin; Xingwei Sui; Eric Chen; Catherine G Lindgren; Brian Till; Andrew Raubitschek; Stephen J Forman; Xiaojun Qian; Scott James; Philip Greenberg; Stanley Riddell; Oliver W Press
Journal:  Hum Gene Ther       Date:  2007-08       Impact factor: 5.695

3.  Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

Authors:  Thomas E Witzig; Leo I Gordon; Fernando Cabanillas; Myron S Czuczman; Christos Emmanouilides; Robin Joyce; Brad L Pohlman; Nancy L Bartlett; Gregory A Wiseman; Norman Padre; Antonio J Grillo-López; Pratik Multani; Christine A White
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

4.  Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.

Authors:  Franck Morschhauser; John Radford; Achiel Van Hoof; Umberto Vitolo; Pierre Soubeyran; Herve Tilly; Peter C Huijgens; Arne Kolstad; Francesco d'Amore; Marcos Gonzalez Diaz; Mario Petrini; Catherine Sebban; Pier Luigi Zinzani; Marinus H J van Oers; Wim van Putten; Angelika Bischof-Delaloye; Ama Rohatiner; Gilles Salles; Jens Kuhlmann; Anton Hagenbeek
Journal:  J Clin Oncol       Date:  2008-10-14       Impact factor: 44.544

5.  Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial.

Authors:  K M Ardeshna; P Smith; A Norton; B W Hancock; P J Hoskin; K A MacLennan; R E Marcus; A Jelliffe; G Vaughan; D C Linch
Journal:  Lancet       Date:  2003-08-16       Impact factor: 79.321

6.  Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis.

Authors:  Lan V Pham; Archito T Tamayo; Linda C Yoshimura; Piao Lo; Richard J Ford
Journal:  J Immunol       Date:  2003-07-01       Impact factor: 5.422

7.  The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.

Authors:  Sandra J Strauss; Karen Higginbottom; Simone Jüliger; Lenushka Maharaj; Paul Allen; David Schenkein; T Andrew Lister; Simon P Joel
Journal:  Cancer Res       Date:  2007-03-15       Impact factor: 12.701

Review 8.  Apoptosis pathways in cancer and cancer therapy.

Authors:  Klaus-Michael Debatin
Journal:  Cancer Immunol Immunother       Date:  2004-01-29       Impact factor: 6.968

9.  Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.

Authors:  Thomas M Habermann; Izidore S Lossos; Glen Justice; Julie M Vose; Peter H Wiernik; Kyle McBride; Kenton Wride; Annette Ervin-Haynes; Kenichi Takeshita; Dennis Pietronigro; Jerome B Zeldis; Joseph M Tuscano
Journal:  Br J Haematol       Date:  2009-02-24       Impact factor: 6.998

Review 10.  The biology of CD20 and its potential as a target for mAb therapy.

Authors:  Mark S Cragg; Claire A Walshe; Andrey O Ivanov; Martin J Glennie
Journal:  Curr Dir Autoimmun       Date:  2005
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.